- Global Pharma News & Resources

BTR Rebrands as Company That Life Sciences and Healthcare Innovators Can Sware By

Sware leading the way in an industry-wide transition to Validation 4.0

BOSTON--(BUSINESS WIRE)--Leading digital validation company, BTR (Boston Technology Research), announced today a rebrand and name change to Sware, Inc. The new name is inspired by the organization’s commitment to trust and transparency and reflects not only the evolution of the brand but also the industry at large.

Sware is a tech-first company, transforming compliance in life sciences and supporting an industry-wide transition from an inefficient, manual approach to an automated, workflow-driven, data-centric solution. The rebrand signifies the company’s position at the center of one of the most innovative sectors - delivering process automation and a single source of validation truth for customers who want ground-breaking results.

“We’ve grown fast - in terms of size, capability, and technologies - and the old BTR brand does not reflect who we are and what we do. Our transformation to Sware is the next step in our evolution as a leader in Validation 4.0,” said Bryan Ennis, Sware CEO and co-founder. “We want a brand that represents the agility and innovation required for positive disruption, along with the passion and ambition of our team of life sciences and healthcare experts who are partnering with our customers to refine the industry – with validation to Sware by.”

Validation 4.0 – a holistic and integrated approach to validation – is the future of compliance across regulated industries, instilling trust and quality in the new technologies of Pharma 4.0™. By driving the end-to-end validation process, Sware’s platform enables painless adoption of emerging technologies for healthcare, life sciences, and SaMD companies. With advanced technology and automation, Sware ensures consistency in compliance and keeps companies in a state of inspection readiness.

Sware’s digital platform, Res_Q, automates, integrates, and scales compliance processes across organizations. Sware’s marketplace provides pre-built compliance modules and ready-to-use templates, SOPs, test scripts and workflows. In addition, Sware works directly with each partner every step of the way, helping to accelerate compliance and deliver speed to users across the enterprise. This approach is critical to Validation 4.0, empowering public trust in the way products are brought to market.

“Pharma 4.0 holds the potential to bring vital changes to the life sciences and healthcare sectors. But Pharma 4.0 simply cannot advance without Validation 4.0,” said Julian Marcu, senior associate at Insight Partners. “The industry is on the cusp of a major transformation with Validation 4.0 and its promise to revolutionize compliance and support the advancement of the broader industry ecosystem. The name Sware so clearly represents that promise.”

News of the Sware rebrand follows a Series A funding announcement earlier this year backed by Insight Partners, LRV Health, and NewStack Ventures.

About Sware

Sware is a leading digital validation company for the life sciences and healthcare industries. Its end-to-end compliance platform de-risks the acceleration of products to market through validation automation. Sware is the validation engine behind leading software providers including Veeva, Benchling, Nuvolo, and Arkivum among others. Sware has helped more than 275 healthcare and life sciences companies transition to the regulated cloud. Sware is headquartered in Chelsea, MA, with a global workforce located throughout North America and Europe.

To learn more about the company’s seamless validation solutions or see a demo, please visit, email the team at, or follow Sware on LinkedIn and Twitter.

* Pharma 4.0 is a trademark and brand of International Society for Pharmaceutical Engineering, Inc. (ISPE)



Terri Leigh Rhody
VP, Marketing, Sware, Inc.
+1 608 683 4801

Marla Kertzman
+1 408 482 3546

Editor Details

  • Company:
    • Businesswire
Last Updated: 11-Oct-2022